2951 - Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy

Background

CMB305 is an active immunotherapy regimen designed to generate and expand anti-NY-ESO-1 T and B cells. It consists of priming with a dendritic cell-targeting lentiviral vector encoding NY-ESO-1, and a boost with NY-ESO-1 recombinant protein plus TLR-4 agonist. This first-in-human study of CMB305 examined safety, immune response (IR), and efficacy in pts with NY-ESO-1 positive (+) solid tumors. At ASCO2017, median overall survival (OS) for soft tissue sarcoma (STS) was not reached (12 mos OS rate 83%).

Methods

Adults with previously treated NY-ESO-1+ solid tumors were enrolled in a 3 + 3 dose-escalation with an expansion phase 1b study. The CMB305 regimen included 4 intradermal injections of the prime, alternating with 3 intramuscular boost injections over 3 months, then bimonthly boost injections up to 1 yr. An updated STS survival analysis was performed.

Results

As of 06 April 2018, 25 pts with STS (15 synovial (SS), 8 myxoid/round cell liposarcoma (MRCL), 2 other) were evaluable for safety; 24 pts were evaluable for IR and efficacy. All pts received prior therapy for advanced disease, 67% > =2 prior chemo regimens. No dose limiting toxicities were observed. Most treatment related adverse events were Grade 1 or 2; one Grade 3 (prostatic pain); no grade 4 or 5 events. Best tumor response was stable disease in 8/15 (53%) SS pts and 6/8 (75%) MRCL pts with evidence of tumor growth arrest. The median progression free survival (PFS) was 3.9 mos (2.1, 7.5) for STS and 3.7 mos (2.1, 7.8) for SS. Median OS was 23.7 mos (15.5, NR) for STS and 29.2 mos (12.2, NR) for SS. Presence of anti-NY ESO 1 antibodies (Ab) at baseline (25.0% pts) was associated with longer survival. Anti-NY-ESO-1 specific T cells and Ab developed in 46% and 67% STS pts, respectively. Pts with baseline and induced anti-NY-ESO-1 IR (T-cells and/or antibodies) had a trend to improved clinical outcomes. T cell receptor sequencing indicated increased clonality and antigen spreading was observed.

Conclusions

CMB305 is well tolerated, broadly immunogenic, and impacts patient survival favorably when compared with approved agents for recurrent STS. These results support a randomized phase 3 trial evaluating CMB305 in the maintenance setting after 1st line therapy in SS patients.

Clinical trial identification

NCT02387125.

Legal entity responsible for the study

Immune Design Corp.

Funding

Immune Design Corp.

Editorial Acknowledgement

None

Disclosure

S.P. Chawla: Advisory board: Amgen, Immune Design, Novartis, PharmaMar, Janssen, Five Prime; Research funding: Amgen, Novartis, Immune Design, Five Prime, Roche, Karyopharm, BMS, Janssen, Blueprint Medicines, PharmaMar, CBA; Stock ownership: EOI, Cellestia, Uptick, Health Centerpoint, Biomedica. M. Druta: Consulting/advisory board: Eisai, Lilly. C. Bohac: Employee, stock ownership: Immune Design, Amgen. H. Lu: Employee, stock ownership: Immune Design. N. Somaiah: Advisory board: Immune Design. All other authors have declared no conflicts of interest.